REGENXBIO Announces Presentations at the 18th Annual WORLDSymposium™ 2022
- Monday, January 31, 2022, 7:11
- PR Newswire
- Add a comment
ROCKVILLE, Md., Jan. 31, 2022 /PRNewswire/ — Interim data from Phase I/II trials of RGX-121 for the treatment of MPS II and RGX-111 for the treatment of MPS I to be presented REGENXBIO Inc. (Nasdaq: RGNX) today announced that five oral and seven poster presentations will be presented at…
About the Author
admin has written 20650 stories on this site.